Table 1.
Pro- and anti-inflammatory effects of different GPR55 ligands.
Compound | Observed effects | |||
---|---|---|---|---|
Agonists | Upregulated | Unchanged | Downregulated | Study |
O-1602 | Neurogenesis, neuronal formation | microglial activation | [68] | |
IL-4, IL-10 | Inflammasome activation, IL-1β, IL-6, TNFα | [70] | ||
Anxiety-like behavior | [42, 70] | |||
Depression-like behavior | [41, 70] | |||
PGE2 | [71] | |||
hippocampal & frontal GPR55 expression | RhoA/ROCK2, IL-1β, TNFα, neuronal apoptosis, cognitive impairment | [84] | ||
IL-1β, IL-6, TNFα, Acetylcholinesterase (AChE) activity, microglial activation | [85] | |||
NF-κB signaling, IL-1β, IL-6, TNFα, GPR55 downregulation, neuronal apoptosis, cognitive impairment | [86] | |||
LPI | IL-1β, IL-2, IL-10, IL-12, IFNγ | IL-6, TNFα | [69] | |
CID1792197 | Cell growth | Cell growth in CB1-GPR55 heterodimer cells | [88] | |
Antagonists | ||||
ML 193 | Anxiety-like behavior | [42] | ||
PGE2 | [71] | |||
CID16020046 | IL-6, COX-2 | [72] | ||
Coumarin derivates | PGE2, COX-2, (IL-6) | [60, 71, 79] | ||
CBD | Antipsychotic effects | [81] |